factor with bi-modal DNA-binding specificity. Here, we demonstrated that Kaiso expression is inversely correlated with glucocorticoid receptor (GR) expression in breast carcinomas. Knockdown of Kaiso increased GR expression, while overexpression of Kaiso inhibited GR expression in breast cancer cells. Furthermore, Kaiso repressed GR proximal promoter-reporter activity in a dose-dependent manner. Remarkably, ChIP experiments demonstrated that endogenous Kaiso was associated with the GR promoter sequence in a methylation-dependent manner. Since glucocorticoids inhibit chemotherapyinduced apoptosis and have been widely used as a co-treatment of patients with breast cancer, we assessed the role of Kasio in GR-mediated anti-apoptotic effects. We found that overexpression of Kaiso attenuated the anti-apoptotic effects of glucocorticoids in breast cancer cells. Our findings suggest that GR is a putative target gene of Kaiso and suggest Kaiso to be a potential therapeutic target in GC-combination chemotherapy in breast cancer. [BMB Reports 2016; 49(3): 167-172]
INTRODUCTION
Kaiso is a POZ-ZF transcription factor originally identified as a binding partner of the cell adhesion molecule p120-catenin (1) . It contains a POZ domain at its N-terminal to mediate protein-protein interactions and zinc finger motifs at its C-terminal to mediate DNA binding. Kaiso can either bind DNA in a sequence-specific manner via the consensus Kaiso binding site (KBD) CTGCNA or directly interact with methylated CpG-dinucleotides to regulate its target gene expression (2) . Kaiso functions primarily as a transcriptional repressor (3) (4) (5) . In breast cancer, nuclear Kaiso expression was associated with poor prognostic factors and invasive breast carcinoma (6, 7) . It has been reported that Kaiso binds directly to methylated sequences in the E-cadherin promoter to promote the epithelialmesenchymal transition in breast cancer (7) . However, the downstream target genes of Kaiso in breast cancer remain to be further characterized.
The glucocorticoid receptor (GR) belongs to the nuclear receptor superfamily of transcription factors (8) . Glucocorticoids are the main ligand for GR, in addition to other ligands including progesterone and dehydroepiandrosterone. Activation of GR by its ligands induces the expression of many genes involved in anti-inflammatory signaling pathways (8) . GR also exerts an anti-apoptotic effect in breast cancer through activation of NF-B or AP-1 (9, 10) . The expression of GR is observed at all stages from normal to cancerous breast tissue and its level generally decreases during cancer progression (11) . A study of breast carcinomas found that the GR proximal promoter was methylated in 15% of tumor samples, while no GR promoter methylation was observed in normal breast tissues (12) . Activation of GR in preclinical human breast cancer models exerted an anti-proliferative effect, while deregulation of the GR signaling pathway promoted tumorigenesis (11) . Thus, GR may function as a tumor suppressor in tumor development (13, 14) .
Although the GR promoter has been reported to be methylated in multiple human cancers, including breast cancer (12, 15, 16) , little is known about its transcriptional regulation by other DNA-binding factors. In this study, we demonstrate that Kaiso represses GR expression by binding to the GR proximal promoter in a DNA methylation-dependent manner. Our study further shows that overexpression of Kaiso attenuates the anti-apoptotic activity of glucocorticoids in breast cancer cells. http://bmbreports.org
MATERIAL AND METHODS

Reagents
Antibodies to Kaiso (6F/6F8), Glucocorticoid Receptor (BuGR2), phosphor-p65 (ab86299), p65 (ab16502), and Sgk-1 (ab59337) were purchased from Abcam (Cambridge, MA, USA). Antibody to -actin was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Human TNF- was purchased from R&D Systems (MN, USA). Other reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Constructs
Human Kaiso and GR full-length sequences were amplified from reverse transcribed cDNA of MCF-7 cells. Then, the Kaiso and GR sequences were cloned into the pCMV-Tag 2A (Agilent Technology, USA) and pCMV-Myc (Clonetech, USA) mammalian expression vectors, respectively. DNA sequencing confirmed the sequence fidelity. A pair of PCR primers was used to amplify the region of the 3 kb GR proximal promoter between −1668 and −4667. PCR products were ligated into a T/A cloning vector and sequenced to confirm sequence fidelity. Then, the 3 kb GR proximal promoter fragment was subcloned into the pGL3-basic plasmid (Promega, USA).
Cell lines
The human breast cancer cell lines BT-20, MDA-MB-231, MCF-7 and T47D were purchased from ATCC and cultured at 37 o C with 5% CO2 in DMEM Medium (Invitrogen, USA) supplemented with 10% fetal bovine serum, 100 units/ml penicillin G, 100 µg/ml streptomycin, and 2 mM L-glutamine.
Western blotting
Cells were lysed in M2 lysis buffer (150 mM NaCl, 50 mM Tris-Cl (pH 8.0), 5 mM EDTA, 1% Nonidet P-40) containing a protease inhibitor mixture (Roche Applied Science) and a phosphatase inhibitor mixture (Sigma，MO, USA). An equal amount of total protein was subjected to SDS-PAGE analysis and immunoblotting using the appropriate antibodies.
Transient transfection, luciferase assay and siRNA knockdown
Following the manufacturer's instructions, plasmids were transfected into cells using Lipofectamine 2000 (Invitrogen, USA). For luciferase assay, 0.8 g of reporter plasmids plus 0.05 g of pCMV-LacZ vector and FLAG-Kaiso or empty vector were transfected into cells using Lipofectamine 2000. At 24 h post-transfection, cells were analyzed for luciferase activity. Luciferase assays were performed using the luciferase assay system (Promega); -galactosidase activity was used as an internal control. Each experiment was conducted in at least triplicate.
For siRNA treatments, T47D cells were plated in a 3.5 cm dish and transfected with 50 pm Kaiso or non-targeting siRNA (Human ONTARGETplus siRNA pools of four oligos, Dharmacon, USA) using Lipofectamine RNAi Max (Invitrogen, USA). After transfection for 48 h, cells were subjected to western blotting.
ChIP Assay
The ChIP assay was performed using the ChIP assay kit from Upstate Biotechnologies, Inc. (Lake Placid, NY). Cells (1 × 10 6 ) were fixed with 1% formaldehyde for 10 min, chromatin was fragmented by sonication to yield fragments between 200 and 1,000 bp, and 10 l of the chromatin solution were saved as input. One microgram of antibody or control immunoglobulin G was added to tubes containing 900 l of chromatin solution. After incubation, the antibody complexes were captured with protein A-agarose beads and subjected to serial washes. The chromatin fraction was further extracted, and the cross-linked chromatin was reversed at 65 o C in the presence of 200 mM NaCl. The DNA was then purified using chloroform/isoamyl alcohol. The PCR primers used to amplify the GR proximal promoter regions were as follows: P1 set, fwd: 5'-GCAACGCACA GAGTCGAGGG C-3', rev: 5'-CGCCCAATGT GCTCACACTCG-3', P2 set, fwd: 5'-CCCCGGGCCCAAAGTA-CGTATGCG-3', rev: 5'-GCGGCTGAGCTGCGTGAGTGG-3', P3 set, fwd: 5'-CGAGTGTGTG CGCGCCGT-3', rev: 5'-CGG-CGTCTCC TTCCACCCAC-3', P4 set, fwd: 5'-CCGCCGCGGG AGCCTACAAA-3', rev: 5'-ACGAAAACGG GTGTCGGGCG-3. PCR products were then run on an agarose gel, stained with ethidium bromide, and photographed.
Real-time PCR
Tumor and normal breast clinical tissue samples were obtained from the second hospital affiliated to XiangYa, Changsha, Hunan, China. This study was approved by the Research Ethics Committee of Second Xiangya Hospital, Hunan, China. Informed consent was obtained from all of the patients. TRIzol reagent (Invitrogen, USA) was used to isolate total RNA. cDNA was prepared using reverse transcriptase SuperScript III (Invitrogen, USA) and 2 g of total RNA. Then, 2 l of cDNA were added to an 18 l PCR assay mixture containing 0.5 M each probe and 10 l Taqman Master Mix (Life Technologies, USA). PCR was conducted with the MyiQ Real-Time PCR Detection System (Bio-Rad, USA). Taqman probes for Kaiso (Assay ID: Hs.PT.58.3381372), GR (Assay ID: Hs.PT.58.27480377), ICAM-1 (Assay ID: Hs. 00164932), IAP-2 (Assay ID: Hs. 00985029) and Actin (Assay ID: Hs.PT.56a.21538384) were purchased from Life Technologies. The threshold cycle number for each gene was normalized to that of -actin, and the resulting value was converted to a linear scale. All assays were performed in at least triplicate from independent RNA preparations.
Statistical analysis
Data were analyzed using the SPSS (version 20.0; IBM Corporation, Armonk, NY, USA) software. Results are expressed as means ± S.D. and are representative of at least three independent experiments. The two-sample t-test was used to de-http://bmbreports.org BMB Reports termine the significance of differences in the means of two columns. A P value less than 0.05 was regarded as indicative of statistical significance.
RESULTS
Kaiso expression inversely correlates with GR expression in breast carcinomas
To study the functional relationship between the transcription factor Kaiso and GR in breast cancer, we first examined the mRNA levels of Kaiso and GR in human breast carcinomas. A total of 32 breast carcinoma samples were collected, which comprised 26 infiltrating ductal carcinomas (IDC), 4 ductal carcinomas in situ (DCIS) and 2 invasive lobular carcinomas (ILC). Interestingly, we found that Kaiso expression was inversely correlated with GR expression in breast cancer samples (Fig. 1A) . To confirm this observation, immunoblotting analysis was performed using a further seven IDCs and one normal breast tissue. As shown in Fig. 1B , tumor samples with lower expression of Kaiso showed elevated expression of GR (Fig. 1B) .
Kaiso represses GR expression in breast cancer cells
As Kaiso expression was inversely correlated with GR expression in breast tumor samples, we then determined whether Kaiso negatively regulates the expression of GR in breast cancer. We found that Kaiso expression was also inversely associated with GR expression in various breast cancer cell lines ( Fig. 2A) . Since T47D cells showed the highest Kaiso expression among all breast cancer cell lines, we then used siRNA to knockdown Kaiso expression in the cells to investigate the regulatory effects of Kaiso on GR expression. As shown in Fig. 2B , knockdown of Kaiso increased GR expression in T47D cells. Furthermore, overexpression of Kaiso in breast cancer cells inhibited GR expression ( Fig. 2C and D) . Since Kaiso is a transcriptional repressor, we then employed a http://bmbreports.org GR promoter luciferase assay to test whether Kaiso influenced the transcriptional activity of the GR promoter. We found that overexpression of Kaiso decreased the promoter activity of GR in a dose-dependent manner (Fig. 2E) . Collectively, our data suggested that Kaiso inhibited GR expression and its promoter activity in breast cancer cells.
Kaiso binds to the GR promoter sequence via a methyl-CpG-dependent mechanism
Since Kaiso can bind DNA in both a sequence-and methyl-CpG-specific manner, we then determined whether Kaiso repressed GR promoter activity by directly interacting with its promoter sequence. The GR proximal promoter is located in a 3 kb CpG island upstream of the translation start site and contains seven alternative first exon sequences, including exon 1B and 1C (gray boxes) (Fig. 3A) . In breast cancer cells, expression of GR transcripts originated from either promoter 1B or promoter 1C (12) . Since there is no Kaiso-binding site in the GR proximal promoter region and the GR promoter is methylated in breast cancer cells (12), we then determined whether Kaiso could bind DNA in a methyl-CpG-dependent manner. Four sets of primers specific for CpG islands in the GR promoter were designed and named P1 to P4 (Fig. 3A) . We first overexpressed FLAG-Kaiso in MCF-7 cells and found that overexpressed Kaiso associated with the P1 and P3 promoter regions (Fig. 3B) . To confirm this result, we used a Kaiso-specific monoclonal antibody 6F to perform a ChIP analysis in T47D cells, which express a high level of Kaiso. We found that Kaiso bound directly to all four promoter sequences in different regions ( Fig 3C) . To test whether Kaiso bound to the GR promoter in a methylation-dependent manner, we treated T47D cells with the DNA demethylation reagent 5-AZ for 48 h. Treatment with 5-AZ did not change Kaiso expression (Fig.  3D) ; however, 5-AZ abolished binding of Kaiso to the GR promoter (Fig. 3E) , suggesting that Kaiso binds to the GR promoter via a methyl-CpG-dependent mechanism.
Kaiso represses the anti-apoptotic effect of GR signaling in breast cancer cells
It has been reported that glucocorticoids (GCs) initiate an anti-apoptosis signaling pathway and protect breast cancer cells from apoptosis (17, 18) . To study the role of Kaiso in the anti-apoptotic effects of the GR signaling pathway, we overexpressed Kaiso in MCF-7 cells and then induced apoptosis by growth factor deprivation (Fig. 4A) or TNF- treatment (Fig.  4B) . We found that overexpression of Kaiso significantly attenuated the anti-apoptotic effects of DEX ( Fig. 4A and B) . To determine whether Kaiso antagonized cell survival specifically through GR, we co-expressed GR in Kaiso-overexpressing MCF-7 cells (Fig. 4C) , and found GR overexpression restored the anti-apoptotic effect of DEX (Fig 4D) . Previous studies demonstrated that GC activated the NF-B signaling pathway in breast cancer cells and induced expression of several anti-apoptosis genes, including sgk-1, bcl-xL and bak (17) (18) (19) (20) . To further investigate the role of Kaiso in regulation of the GR signaling pathway, we then analyzed p65 phosphorylation and sgk-1 expression in Kaiso-overexpressing cells. Consistent with http://bmbreports.org BMB Reports previous studies, DEX induced phosphorylation of p65 and sgk-1 expression in control cells, while overexpression of Kaiso inhibited phosphorylation of p65 and sgk-1 expression (Fig.  4E) . Importantly, co-expression of GR with Kaiso restored the DEX-induced phosphorylation of p65 and sgk-1 expression, suggesting a regulatory role for Kaiso in the GR signaling pathway by targeting GR expression (Fig. 4E) . Furthermore, overexpression of Kaiso also inhibited expression of NF-B-induced anti-apoptotic target genes, including ICAM-1 and cIAP2 (Fig. 4F ).
DISCUSSION
As a stress hormone (glucocorticoid) receptor, GR plays an important role in breast cancer cell biology (11) . Since GR is the key mediator of cellular responses to GCs, its expression must be strictly regulated. In this study, we found that expression of the POZ-ZF transcription factor Kaiso was inversely correlated with GR expression in most invasive ductal carcinomas (IDC). The nuclear expression of Kaiso in IDC has been shown to be related to poor prognostic factors, including high grade, poor differentiation and metastasis (6, 7) , while in ILC, most Kaiso proteins are localized in the cytoplasm and may function as a tumor suppressor (6) . Since most tumor samples in this study were from IDC (80.1% IDC samples, 26/32), our results most likely represented the nuclear function of Kaiso in breast cancer. As a transcriptional repressor, Kaiso could function as an oncogene to inhibit expression of tumor suppressor genes in multiple types of cancer. In colon cancer, Kaiso inhibited expression of the tumor suppressor gene CDKN2A by binding to its methylated promoter (21) . It has been reported that Kaiso promotes breast cancer metastasis by binding to the methylated sequences in the E-cadherin promoter (7). However, Kaiso target genes in breast cancer still largely unknown. Our findings suggested that GR was a novel Kaiso target gene and supported an oncogenic role for Kaiso in breast cancer.
Kaiso is a dual-specificity transcription factor exhibiting DNA sequence-and methyl-CpG-specific transcriptional suppression activity. The human GR gene is regulated by two distinct promoter regions, the distal promoter and the proximal promoter (22) . In breast cancer, the proximal promoter is predominantly responsible for GR expression (12) . The proximal promoter has been shown to be methylated in gastric, lung, and breast cancers (12, 15) . Loss of GR expression was associated with the methylation of its promoter and may contribute to tumorigenesis of breast cancer (12) . We found that Kaiso was associated with the GR proximal promoter sequence in a methylation-dependent manner. Similarly, Kaiso regulates several tumor-associated genes, including CDH1 (E-cadherin) and CDKN2A, in methylation-dependent manner (7, 21, 23) . In addition, our results demonstrated that overexpression of Kaiso was associated with the P1 and P3 promoter regions in MCF-7 cells, while endogenous Kaiso was associated with all four promoter regions (P1 to P4) in T47D cells. The different affinity of Kaiso for GR promoter sequences may reveal the different levels of methylation of the GR promoter between MCF-7 and T47D cells. Thus, our data indicated GR to be a downstream target gene of Kaiso and may suggest a molecular mechanism for the transcriptional regulation of GR expression in breast cancer cells.
GCs have been used extensively as a co-medication with chemotherapy in breast cancer. These hormones have been shown to reduce inflammation and protect healthy tissues http://bmbreports.org from cytotoxic side effects of the chemotherapy (11) . Furthermore, the activation of GR by its ligands initiates an anti-apoptotic signal in several types of cancer, including breast cancer (14, 17, 18) . Our data demonstrated that Kaiso overexpression attenuated the anti-apoptotic effects of GR activation. The expression of Kaiso may have prognostic value in GC-combined chemotherapy in breast cancer. In future, it would be interesting to study the clinical role of Kaiso in GC-combined chemotherapy.
Our findings demonstrated that Kaiso inhibited GR expression by associating with the GR promoter sequence in a methylation-dependent manner in breast cancer. Importantly, a functional study suggested that Kaiso functioned as a suppressor in the GR signaling pathway. As GR plays important roles in breast cancer development and chemotherapy, our study suggests Kaiso to be a potential therapeutic target in breast cancer.
